Cetirizine injection - ESTEVE
Alternative Names: JDP-205; JDP-205 Al; JDP-207; QUZYTTIR; QZYTIRLatest Information Update: 24 Mar 2026
At a glance
- Originator JDP Therapeutics
- Developer TerSera Therapeutics
- Class Acetic acids; Antiallergics; Benzyl compounds; Chlorobenzenes; Eye disorder therapies; Nonsedating antihistamines; Piperazines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Urticaria
- Phase II Hypersensitivity
Most Recent Events
- 10 Mar 2026 Esteve acquires Cetirizine injection from TerSera Therapeutics
- 03 Jun 2021 Updated efficacy and adverse events data from a phase II trial in Hypersensitivity presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 05 Mar 2021 Efficacy and adverse events data from a phase II trial in Hypersensitivity released by TerSera Therapeutics